Mirzaten (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral administration. It enhances noradrenergic and serotonergic neurotransmission and is primarily prescribed for the management of major depressive disorder in adult patients who require a rapid improvement in mood and sleep quality.

GNH USA supplies Mirzaten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for global health partners.

Mirtazapine is used to treat depressive disorders by modulating noradrenergic and serotonergic pathways.

Major depressive disorder: reduces core depressive symptoms and improves sleep in adult patients. Depressive symptoms with comorbid insomnia: helps improve sleep quality while treating depression. Adjunctive therapy for treatment‑resistant depression: may be added when response to first‑line antidepressants is inadequate.

Mirtazapine may cause a range of adverse reactions that vary in frequency.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Serotonin syndrome, especially with other serotonergic agents - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or worsening depression - Abnormal liver function tests

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly. - Psychiatric assessment: screen for suicidal ideation and worsening depression. - Hepatic function: adjust dose or monitor in patients with liver impairment. - Elderly patients: start at low dose and monitor for excessive sedation. - Discontinuation: taper gradually to avoid withdrawal symptoms. - Concomitant CNS depressants: use caution due to additive sedation. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome; discontinue MAOI at least 14 days before starting. - Linezolid or methylene blue: potent serotonergic activity may precipitate serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CNS depressants (alcohol, benzodiazepines): additive sedation and respiratory depression. - Other serotonergic agents (SSRIs, SNRIs, tramadol): monitor for signs of serotonin syndrome. - Anticholinergic drugs: may exacerbate dry mouth and constipation. - Warfarin: occasional reports of altered INR; monitor coagulation parameters.